c | u | dose | days | model |
---|
c | u | dose | every | model |
---|
The cloud does not represent data points, it is a visual representation of the uncertainty in the model itself and it underestimates the total uncertainty. It only captures the uncertainty of something akin to a population mean, or more precisely the uncertainty over the parameters of the deterministic estradiol curve. It does not capture the full distribution of outcomes in the population at large. This is bound to change in the future once a better representation of this uncertainty gets implemented (which would include the additional population variability around the deterministic curve).
The emerging consensus is that the pharmacokinetics of estradiol ester depots is highly variable and depends on many factors that are not well understood and rarely taken into account. Those factors can lead to vastly different outcomes and are not well represented, if at all, in the current models. Those include, among others, the ester concentration, the type of oil used, the proportion and type of excipients such as benzyl benzoate that are present in the formulation, the injection site, whether the depot is injected intramuscularly or subcutaneously, the injection depth, individual differences in metabolism, and the presence of other drugs. Some of those confounding factors are sometimes captured to an extent in the uncertainty of the models, but only when the data is abundant and spans multiple studies done under different conditions. This is, of course, generally not the case. Several of those factors also apply to transdermal, oral, and sublingual estradiol. I am actively working to improve and generalize the current models in ways that will better capture this variability, but ultimately their accuracy and scope will always be limited by the data available.
Inferences for the estradiol benzoate, valerate, and cypionate intramuscular depot models (eb im, ev im, ec im) use part of the data collected and made available by the amazing people behind the tfs meta-analysis but will be reprocessed in the future to allow for a better quantification of uncertainty.
The data behind the estradiol undecylate model for intramuscular depots using castor oil (eun im) was entirely reprocessed from scratch using the per-patient data found in Geppert 1975 together with the data and uncertainty reported in Vermeulen 1975. This data is extremely sparse and incomplete and thus the model is highly uncertain.
The data behind the estradiol undecylate model for subcutaneous depots using castor oil (eun casubq) was inferred on top of the eun im model by augmenting it with very sparse self-reported community data. Its predictions are also highly uncertain.
The data behind the estradiol enanthate model for intramuscular depots using sunflower oil (een im) was reprocessed from scratch using studies with Perlutan from the 80s and 90s. This data is also extremely sparse and incomplete and the model highly uncertain.
The once-weekly patch model (patch ow) was inferred using data found in drug labels of once-weekly Climara and Menostar patches. The twice-weekly patch model (patch tw) was inferred using data taken from two 2003 studies by Houssain et al. looking at twice-weekly Estradot and Menorest patches, and in the drug label of twice-weekly Mylan patches. In light of knowledge gathered from self-reported community data, please be advised that both models excessively underestimate the uncertainty which should be close to 10 times larger. The models will be improved to better reflect this in the future. Currently there is no way to change the wearing period of the patch in the interface (i.e. they are fixed at 3½ and 7 days) but it is planned for the future.
The data for the menstrual cycle comes from Stricker et al. 2006. Download the E2/P/LH/FSH data.
Data for target ranges is based on guidance from WPATH Standards of Care, Version 8 in addition to the Endocrine Society's Clinical Practice Guideline.
Note regarding "inapproprite WPATH regimens" presets
In the WPATH Standards of Care (Appendix C, page S254), several hormone replacement therapy (HRT) regimens for transfeminine people are listed. However, some of these recommendations might not align with WPATH's own guidelines and could even be harmful. Here's a breakdown of the issues.
estrannaise.js is entirely client-side. Your data, whether entered, imported, or stashed, remains exclusively within your browser and will never be transmitted to the developer(s) or any third-party by our application.
estrannaise.js (v0.3.6) JavaScript license information mit license (c) 2024 alix
If this kind of thing interests you, you can contact me on signal a1ix2.91 or by email _a1ix2_at_proton_dot_me_ (no underscores). For feedback, bugs, and feature requests submit an issue on github.
tipjars (click address to copy) xmr85Tz3LXEU65h6Lf6tjXLk744FMYW5f4yeTx1pVjsqURQ3YQxtawQJoMAcXDAtEbyFhBLZeEdsXGmpTy5RzzDCWQo6QvcvzE btc1EK9wp876WhA8W3m7a1mR1Aka6LDsoWpCR ltcltc1qz4auzjh0dtfqlu5yjk85tvz83aed60ajmy8src eth0xccC52F9E0CFA1D365A69b5D624dA357192bb3c83